Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.65 |
| ▸ | MAOB | P27338 | 13/20 | 0.49 |
| ▸ | MAOA | P21397 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CALML3 | P27482 | 1/20 | 0.47 |
| ▸ | SDHA | P31040 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111260 | 1.00 | KCNH2 (0.65) | KCNH2MAOBMAOALMNAPTGS1 | |
| SCHEMBL5099696 | 0.88 | KCNH2 (0.51) | KCNH2MAOBMAOALMNAPTGS1 | |
| SCHEMBL5099702 | 0.88 | KCNH2 (0.51) | KCNH2MAOBMAOALMNAPTGS1 | |
| SCHEMBL5099716 | 0.88 | KCNH2 (0.51) | KCNH2MAOBMAOALMNAPTGS1 | |
| SCHEMBL5099708 | 0.88 | KCNH2 (0.51) | KCNH2MAOBMAOALMNAPTGS1 | |
| SCHEMBL5098592 | 0.87 | KCNH2 (0.71) | KCNH2MAOBMAOALMNAPTGS1 | |
| SCHEMBL6187424 | 0.87 | KCNH2 (0.71) | KCNH2MAOBMAOALMNAPTGS1 | |
| SCHEMBL5102142 | 0.87 | MAOB (0.55) | KCNH2MAOBMAOALMNAPTGS1 | |
| SCHEMBL5101943 | 0.87 | KCNH2 (0.47) | KCNH2F10 | |
| SCHEMBL5101938 | 0.87 | KCNH2 (0.47) | KCNH2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405228-B2 | Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites | WOCKHARDT LIMITED (IN) | 2008-07-29 | — | — | US | claimed |
| US-20040063954-A1 | Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites | WOCKHARDT LIMITED | 2004-04-01 | — | — | US | claimed |
| US-7405228-B2 | Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites | WOCKHARDT LIMITED (IN) | 2008-07-29 | — | — | US | disclosed |
| US-20040063954-A1 | Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites | WOCKHARDT LIMITED | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063954-A1 | Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites | POLRMT, RNASEL, RNASE1 | KCNH2 3798/4885MAOB 2080/4885MAOA 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.